Akt mediates GSK-3β phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions

NeuroImmunoModulation

Volumn 21, Issue 4, 2014, Pages 183-188

  Zhou, Wei ^a   Dong, Lin ^a   Wang, Nan ^a   Shi, Jin Yun ^a   Yang, Jian Jun ^a   Zuo, Zhi Yi ^b   Zhou, Zhi Qiang ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antidepressant effect; Glycogen synthase kinase 3; Ketamine; Mammalian target of rapamycin; Protein kinase B

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; PF 4708671; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; PHOSPHOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FORCED SWIM TEST; IMMOBILIZATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL MODEL; IMMOBILITY; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOTTING, WESTERN; GLYCOGEN SYNTHASE KINASE 3; KETAMINE; MALE; PHOSPHORYLATION; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84893686765     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000356517     Document Type: Article

References (30)

1. Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 2008; 455: 894-902.
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR * D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR * D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
3. Zarate CA Jr , Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864. (Pubitemid 44188478)
4. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA: Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946.
5. Yang JJ, Zhou ZQ, Yang C: Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines? Psychol Med 2011; 41: 1787-1789.
6. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
7. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K: Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010; 3: 374-391.
8. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102. (Pubitemid 38186580)
9. Kockeritz L, Doble B, Patel S, Woodgett JR: Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7: 1377-1388. (Pubitemid 44718298)
10. Beurel E, Song L, Jope RS: Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011; 16: 1068-1070.
11. Eldar-Finkelman H, Martinez A: GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 2011; 4: 32.
12. Dwyer JM, Lepack AE, Duman RS: mTOR activation is required for the antidepressant effects of mGluR 2/3 blockade. Int J Neuropsychopharmacol 2012; 15: 429-434.
13. Budni J, Lobato KR, Binfare RW, Freitas AE, Costa AP, Martin-de-Saavedra MD, Lea RBl, Lopez MG, Rodrigues AL: Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice. J Psychopharmacol 2012; 26: 714-723.
14. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-391.
15. Freyberg Z, Ferrando SJ, Javitch JA: Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010; 167: 388-396.
16. Wang H, Brown J, Gu Z, Garcia CA, Liang R, Alard P, Beurel E, Jope RS, Greenway T, Martin M: Convergence of the mammalian target of rapamycin complex 1 and glycogen synthase kinase3-β-signaling pathways regulates the innate inflammatory response. J Immunol 2011; 186: 5217-5226.
17. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD: S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006; 24: 185-197. (Pubitemid 44574477)
18. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H: Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-784. (Pubitemid 38429867)
19. Gould TD, Einat H, Bhat R, Manji HK: ARA014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-390. (Pubitemid 39648068)
20. Green HF, Nolan YM: GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia. Neurochem Int 2012; 61: 666-671.
21. Beaulieu JM: A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotoninneurotransmission in mental health. J Psychiatry Neurosci 2012; 37: 7-16.
22. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Markx S, Lieberman JA, Javitch JA: Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010; 31: 381-390.
23. Crowder RJ, Freeman RS: Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000; 275: 34266-34271.
24. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-968. (Pubitemid 44310775)
25. Kirschstein T: Synaptic plasticity and learning in animal models of tuberous sclerosis complex. Neural Plast 2012; 2012: 279834.
26. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC III: A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008; 295:C836-C843.
27. Yang C, Zhou ZQ, Gao ZQ, Shi JY, Yang JJ: Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol Psychiatry 2013; 73:e35-e36.
28. Wilkinson MB, Dias C, Magida J, Mazei-Robison M, Lobo M, Kennedy P, Dietz D, Covington H III, Russo S, Neve R, Ghose S, Tamminga C, Nestler EJ: A novel role of the WNT-dishevelled-GSK3β signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. J Neurosci 2011; 31: 9084-9092.
29. Davis E, Ghosh A: Should I stay or should I go: Wnt signals at the synapse. Cell 2007; 130: 593-596. (Pubitemid 47268065)
30. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA, Lee ME: Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001; 276: 17479-17483.